The history of one of the world's biggest speciality and rare disease pharmaceutical companies Shire is known as one of the world's fastest growing specialty pharmaceutical companies. Today, it ...

Takeda has officially taken over Shire in a deal that could re-establish the trend for mega mergers in big pharma. The merger was approved yesterday in a court hearing in Jersey, where Shire was ...

Ireland’s deputy premier has held a phone call with the US Secretary of Commerce, a major critic of the trade imbalance ...

Asked if Mr Harris had corrected Mr Lutnick on this figure, a spokesman said: “The Tanaiste (deputy premier) set out the ...

Advancements in drug manufacturing technologies are reshaping global regulatory frameworks. This shift is largely driven by the integration of artificial intelligence (AI)-powered models, cloud ...

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

MIRA Pharmaceuticals signs letter of intent to acquire SKNY Pharmaceuticals, adding SKNY-1, a preclinical drug for weight ...

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers ...

Dr. Pujara brings extensive industry experience to guide late-stage development of the SpyGlass Drug Delivery PlatformALISO VIEJO, Calif., March ...

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...

X4 Pharmaceuticals highlights 2024 as transformative with XOLREMDI's U.S. launch, international expansion, & Phase 3 trial progress.

MIRA Pharmaceuticals (MIRA) announced that it has signed a binding letter of intent or LOI to acquire SKNY Pharmaceuticals… The transaction ...